SMITH & NEPHEW

Overview

Smith & Nephew is a UK-founded medical technology company focused on products that repair, regenerate and replace soft and hard tissue, serving healthcare professionals through three global business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Its portfolio includes hip, knee and shoulder replacement systems, trauma and extremities products, robotics-assisted and digital surgical solutions, soft-tissue repair instruments, and wound-care products for complex and hard-to-heal wounds.[1]+4

The company’s mission is framed as “Life Unlimited,” with a stated purpose of restoring people’s bodies and self-belief and using technology to help take the limits off living.[1][6] Founded in Hull, UK, in 1856, Smith & Nephew now serves around 100 countries worldwide.[7][8] In 2024, it reported revenue of $5.81 billion and employed 17,349 people, indicating a sizable global presence in the medical technology sector.[9][10] [1]+9

Products & services

Smith & Nephew’s orthopaedics products cover joint reconstruction, trauma and extremities, and robotics-assisted surgery. The CORI Surgical System is a handheld, portable platform for robotics-assisted knee and computer-guided hip procedures; in knee surgery it uses handheld precision milling and an intra-operative smart-mapping feature to create a 3D image of the patient’s anatomy, avoiding pre-operative CT scans, and it is indicated for partial, total and revision knee arthroplasty. The related CORIOGRAPH pre-operative planning and modelling service adds image-based planning while also supporting image-free registration, allowing surgeons to choose whether to use a pre-operative MRI. Other named reconstruction products include the JOURNEY II total knee arthroplasty system with OXINIUM technology, the LEGION CONCELOC cementless total knee system using 3D-printed technology for biological fixation, and the EVOS plating system, which is designed as a unified platform for mini-, small- and large-fragment trauma surgery.[4]+6

In Sports Medicine & ENT, Smith & Nephew sells soft-tissue repair and resection devices, implants and operating-room technologies. The REGENETEN implant is a porous, oriented scaffold made from highly purified type I collagen fibres that is intended to support the body’s natural healing response and promote tendon-like tissue growth. HEALICOIL anchors use an open architecture intended to reduce implanted material, and versions using REGENESORB are designed for full absorption and bone replacement within 24 months. The PLATINUM Handpiece is designed for removal of dense bone and tissue in large joints and operates with improved torque in a 4,000-10,000 RPM working range. The INTELLIO 4K Connected Tower Solution wirelessly connects and controls major arthroscopy tower components from outside the sterile field, while the WEREWOLF COBLATION system is used for precise soft-tissue removal in arthroscopic procedures.[17]+5

Advanced Wound Management combines wound dressings, infection-management products, and negative pressure wound therapy products and services for hard-to-heal wounds. The PICO range of single-use NPWT systems uses AIRLOCK technology and is described as highly portable while supporting healing in chronic wounds and reducing surgical-site complications. The RENASYS EDGE NPWT system is also part of the portfolio. ALLEVYN LIFE dressings use independent sliding layers to absorb mechanical energy and protect against friction and shear, and the company cites a 66% reduction in the odds of pressure injury development when the dressing is added to prevention protocols. Infection-management products named in the portfolio include ACTICOAT antimicrobial barrier dressings, DURAFIBER Ag absorbent gelling silver fibrous dressings, ALLEVYN Ag antimicrobial foam dressings, and IODOSORB cadexomer iodine products.[23]+4

By business unit, the product mix was diversified in 2024: Orthopaedics generated $2.305 billion of revenue, Sports Medicine & ENT $1.824 billion, and Advanced Wound Management $1.681 billion; the annual report also described this as roughly 40%, 31% and 29% of group revenue, respectively.[28]+3 [4]+21

Geographic presence

Smith & Nephew is headquartered in the UK, with its registered office in Watford, Hertfordshire, and it states that it operates in more than 100 countries across five continents, with the USA as its largest market.[32]+2

For geographic reporting, the company groups revenue into Established Markets and Emerging Markets; Established Markets are defined as the US, Australia, Canada, Europe, Japan and New Zealand.[35] In 2024, Established Markets generated $4,830 million, or 83.1% of total revenue, while Emerging Markets generated $980 million, or 16.9%, out of total revenue of $5,810 million.[36] Sales are attributed to the country of destination; the US accounted for $3,123 million of 2024 revenue, about 53.8% of the total, while the UK contributed $226 million, about 3.9%, and China $210 million, about 3.6%.[37][36]

Its operating footprint includes the group head office and training facility in Watford; manufacturing and office or training facilities in Memphis; a wound management manufacturing, research and office site in Hull; manufacturing sites in Suzhou, Penang, Alajuela, Oklahoma City and Aarau; an R&D and office site in Austin; a logistics facility in Lawrenceville; a business services centre in Pune; and manufacturing, office and laboratory space in Kfar Saba.[38] The group reported 17,349 employees.[10] [32]+7

Business segments

Smith & Nephew organizes its operations around four global business units—Orthopaedics, Sports Medicine, ENT, and Advanced Wound Management—but for IFRS 8 reporting it aggregates Sports Medicine and ENT, resulting in three reportable segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management [39]+2. Based on 2024 external customer revenue of $5,810 million, Orthopaedics contributed $2,305 million (about 40%), Sports Medicine & ENT contributed $1,824 million (about 31%), and Advanced Wound Management contributed $1,681 million (about 29%) [28].

Orthopaedics includes hip, knee and shoulder implants for joint replacement, robotics-assisted enabling technologies such as the CORI surgical system, and trauma products used to stabilize fractures and correct bone deformities; the company also discusses Joint Reconstruction and Trauma & Extremities as key focus areas within this segment [42][43]. Sports Medicine & ENT covers soft-tissue and joint repair solutions, including implants and instruments for arthroscopic procedures across knees, shoulders, hips and small joints, arthroscopic enabling technologies such as visualization, fluid management, COBLATION and mechanical resection, and ENT products based on COBLATION plasma technology [44]+2. Advanced Wound Management is described through three main areas—Advanced Wound Care, Advanced Wound Bioactives, and Advanced Wound Devices—covering exudate and infection management, skin protection and pressure-injury prevention, debridement and dermal repair/tissue substitutes, and device-based therapies including negative pressure wound therapy for chronic wounds and surgical site complications [23]+3. [39]+12

Company history

Smith & Nephew traces its origins to 1856, when Thomas James Smith opened a small pharmacy in Hull, UK; after his death in 1896, management of the business passed to his nephew, Horatio Nelson Smith. The company was later incorporated and listed on the London Stock Exchange in 1937, added a New York Stock Exchange listing in 1999, and became part of the FTSE 100 in 2001.[7]+2

By the late 1990s, Smith & Nephew had expanded into a diverse global healthcare company. In 2011, it combined its Endoscopy and Orthopaedics businesses into an Advanced Surgical Devices division, and in 2015 it brought Advanced Wound Management and Advanced Surgical Devices together into a global business organized across nine product franchises.[51][52]

Its more recent development has included a series of acquisitions that broadened its technology base, including ArthroCare in 2014, Blue Belt Technologies in 2016 after its 2015 announcement, and CartiHeal in 2024. These deals added sports medicine capabilities, robotics-assisted orthopaedic surgery, and cartilage-regeneration technology for the knee, respectively.[53]+2 [7]+7

Sources

• SMITH & NEPHEW — Full financial report (2024 Y)
  51 citations

  [1][2][3][4][5][6][7][8][9][10][11][12][13][14][16][17][18][19][20][21][22][23][24][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][55]
• SMITH & NEPHEW — Full financial report (2023 Y)[15][25]
• SMITH & NEPHEW — Full financial report (2015 Y)[53]
• SMITH & NEPHEW — Full financial report (2016 Y)[54]